Larotrectinib-Enhanced Radioactive Iodine Uptake in Advanced Thyroid Cancer

In a woman with thyroid cancer expressing an EML4-NTRK3 fusion gene, the cancer had become refractory to radioactive iodine when the capacity of the tumors to take up iodine was lost. The use of larotrectinib, an NTRK inhibitor, resulted in a partial response and restored iodine uptake in the tumor...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 383; no. 17; pp. 1686 - 1687
Main Authors Groussin, Lionel, Clerc, Jérôme, Huillard, Olivier
Format Journal Article
LanguageEnglish
Published Boston Massachusetts Medical Society 22.10.2020
Subjects
Cancer therapies
Fusion protein
Iodine
Kinases
Mutation
Scintigraphy
Thyroid cancer
Tumor cells
Tumors
Online AccessGet full text

Cover

More Information
Summary:In a woman with thyroid cancer expressing an EML4-NTRK3 fusion gene, the cancer had become refractory to radioactive iodine when the capacity of the tumors to take up iodine was lost. The use of larotrectinib, an NTRK inhibitor, resulted in a partial response and restored iodine uptake in the tumor cells.
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMc2023094